What Vagistat-3 Treats: Main Uses and Benefits

Vagistat-3 is commonly used to help with localized fungal overgrowth, specifically applied in addressing infections caused by Candida species, medically known as vulvovaginal candidiasis (VVC). This localized therapy is relevant in conditions presenting with symptomatic discomfort. Its primary therapeutic benefit involves contributing to the resolution of the infection, particularly in contexts involving heightened systemic burden.

The medication is commonly used to help with managing symptoms related to inflammatory or irritative states, such as intense vulvovaginal itching, external irritation, and a persistent burning sensation. The specific indications for this type of antifungal treatment include its use for managing vaginal yeast infections and its relevance for easing external vulvar itching and irritation associated with the infection.

“The therapeutic action supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Vagistat-3 is relevant in situations where groups of symptoms appear suddenly or fluctuate, such as the presentation of abnormal vaginal discharge and vulvar redness or swelling. By assisting in the reduction of these localized manifestations, Vagistat-3 helps ease the overall burden of symptoms and contributes to improved comfort during periods of heightened symptoms that interfere with daily functioning.

---

Quick Fact: Addresses Vulvovaginal Itching

This section outlines the official eligibility criteria and population-specific restrictions for Miconazole Nitrate vaginal preparations, as documented in government regulatory labeling. Use is generally permitted for adults and adolescents 12 years of age and over for the treatment of uncomplicated vulvovaginal candidiasis.

---

Contraindicated Populations and Restrictions

Classification	Target Population/Condition
Absolute Contraindication	Patients with known hypersensitivity or allergy to Miconazole Nitrate or any other ingredient in the product.
Use Restricted/Conditional	Children under 12 years of age (use not established).
Conditional Use	Patients with underlying chronic diseases such as diabetes, a weakened immune system (e.g., HIV/AIDS exposure), or a history of frequent yeast infections (recurrence).
Conditional Use	Patients taking the prescription blood-thinning medicine warfarin (requires professional consultation).
Conditional Use	Pregnant or breastfeeding individuals (labeled as 'Ask a health professional before use').

---

Eligibility-Related Limitations

Use is also conditional and requires professional consultation if the patient exhibits severe symptoms such as fever, chills, lower abdominal/back pain, or foul-smelling vaginal discharge, as these may indicate a more serious condition. The medicine is intended only for uncomplicated vulvovaginal candidiasis in the permitted population.

Interactions with other medicines and products

The interaction profile for Vagistat-3, which contains Miconazole Nitrate, is determined by the potential for systemic drug exposure alteration despite its localized, intravaginal use. The active ingredient is a documented inhibitor of Cytochrome P450 enzymes CYP2C9 and CYP3A4 in regulatory labeling, a pharmacokinetic property that may affect co-administered medicines.

Documented Drug-Drug Interactions

Interacting Substance Category	Official Interaction Outcome
Oral Anticoagulants (e.g., Warfarin, Dicumarol)	Enhancement of anticoagulant effect, increasing the risk of bleeding and bruising.
Other CYP-Substrates (e.g., Oral Hypoglycemics, Phenytoin)	Potential for increased plasma concentrations or enhanced effects.

Interaction-Related Restrictions

Official documents mandate specific constraints regarding use with other products.

• Barrier Contraceptives: Vagistat-3 must not be used concurrently with barrier contraceptives (such as condoms or diaphragms). The product's formulation can damage the latex or rubber material, potentially compromising the efficacy of the barrier method.
• Patients on Warfarin: Due to the documented interaction resulting in an enhanced anticoagulant effect, regulatory labeling states that patients taking the prescription medicine Warfarin must consult a doctor or pharmacist before use.

How Vagistat-3 Works

The mechanism of action centers on the inhibition of the fungal cytochrome P450 enzyme 14alpha -lanosterol demethylase ( CYP51). This enzyme is required for synthesizing ergosterol, a critical structural component of the fungal cell membrane. Inhibition of CYP51 blocks ergosterol production, causing toxic sterol intermediates to accumulate while simultaneously altering membrane lipid composition. This dual effect results in a fundamental increase in membrane permeability and a loss of structural integrity.

The compromised membrane integrity triggers a subsequent cascade: essential intracellular components, including potassium ions and phosphates, leak out of the cell. This efflux causes cytoplasmic deterioration and disrupts necessary osmotic balance, ultimately leading to fungal cell necrosis. The drug also modifies factors influencing fungal morphology, limiting the organism's conversion from its yeast form (blastospore) to the filamentous, more invasive mycelium, thereby reducing the fungal capacity for tissue infiltration and biofilm formation.

How to Use Vagistat-3 (Miconazole Nitrate)

This information describes the administration of Vagistat-3, a combination treatment containing Miconazole Nitrate 200 mg vaginal suppositories and 2% external vulvar cream.

Administration and Dosing Schedule

Component	Dosing Rule	Frequency & Duration
Vaginal Suppository	Insert one 200 mg suppository into the vagina.	Once daily at bedtime for 3 consecutive nights.
External Cream	Apply a small amount of 2% cream to the affected area.	Twice daily (morning and bedtime) for up to 7 days, as needed.

Procedural and Course Instructions

Route and Timing: The suppository is for vaginal insertion only and must be administered using the provided disposable applicator immediately prior to sleep. The external cream is for external vulvar application only.

Course Continuity: Complete the full 3-night course of the vaginal suppository, even if symptoms improve quickly or if a menstrual period begins during the treatment course. If a dose is missed, continue with the next scheduled dose at bedtime.

Restrictions During Use: To maintain treatment effectiveness and prevent complications, refrain from using other intravaginal products, such as tampons, douches, or spermicides, during the treatment period. Furthermore, be aware that the oil-based components in the medication may damage latex products; therefore, do not rely on condoms or diaphragms for contraception or STD prevention while using this medication and for several days after.

Research Evidence / Overview of Studies

This section summarizes the research that has investigated the effects of Vagistat-3 (Clotrimazole 200 mg) and how the 3-day treatment regimen was studied in relation to vulvovaginal candidiasis (VVC) symptoms.

---

Clinical Trial Findings

The primary research question for clinical trials was whether Vagistat-3 would be associated with a mycological cure (clearance of Candida species) and a clinical cure (resolution of signs and symptoms) compared to placebo or other regimens.

Efficacy and Dose Regimens

Studies have explored whether the 3-day regimen is associated with changes in VVC symptoms. The typical 3-day treatment course was investigated across multiple randomized, controlled trials.

Study Metric	Key Findings Reported in Trials
Mycological Cure Rate	Rates typically ranged from 80% to 90% in participants who completed the treatment course.
Clinical Cure Rate	Rates commonly ranged from 75% to 85% at follow-up (7–14 days post-treatment).

Trial data suggests that the mycological response (reduction of yeast cells) usually preceded the clinical response (reduction of itching, burning, and discharge).

Tolerability

The most common adverse events reported in clinical trials were local site reactions, such as irritation or burning at the application site. These events were generally reported as mild and transient, meaning they were brief and resolved quickly. Participants rarely discontinued the 3-day regimen due to adverse events, indicating that the regimen was generally well-tolerated across the study populations.

Therefore, the available evidence describes the effects observed when the clotrimazole 200 mg 3-day regimen was investigated for VVC.

Key Studies & References

1. Treatment of Vulvovaginal Candidiasis: A Review of the Evidence

Common questions about Vagistat-3 (FAQ)

Q: Is Vagistat-3 safe to use if I am pregnant?

Official regulatory information states that a health professional should be consulted before using this medicine during pregnancy. Studies have generally examined use during the second and third trimesters, where there has been no specific evidence of harm to the fetus. Regulatory information indicates that use is generally considered only when the potential benefit is determined to outweigh the risk.

Q: Is it safe to use Vagistat-3 if I am breastfeeding?

According to official labeling, a health professional should be consulted before using this medication while breastfeeding. Due to the product's poor systemic absorption, adverse effects on an infant are not commonly expected. However, specific data on whether the drug passes into human milk are not available.

Q: Do you need to use the full 3-day course if symptoms disappear early?

The course is intended for three consecutive days of treatment. Official directions state that if symptoms do not improve within three days, or if they last longer than seven days, a healthcare provider should be consulted. Regulatory guidance describes the full course as the intended treatment period. This approach is consistent with addressing the infection as specified in the directions.

Q: Can Vagistat-3 be used at the same time as other topical creams?

The Vagistat-3 kit includes both an internal suppository and an external cream to be used simultaneously. Regulatory documents caution against using other products that go inside the vagina, such as douches or spermicides. There is no specific instruction about using other external, non-vaginal topical creams.

Q: Is Vagistat-3 the same as Monistat?

Vagistat-3 contains the active ingredient Miconazole Nitrate. Regulatory reviews and product information indicate that this ingredient is also marketed under various brand names, including Monistat, which share the same antifungal substance.

Q: What kind of infections does Vagistat-3 treat?

Official labeling indicates the product is used to treat vulvovaginal candidiasis, which is the medical term for a vaginal yeast infection. The included external cream is intended to relieve the related external itching and irritation.

Q: Can Vagistat-3 be used for things other than yeast infections?

This specific vaginal product is indicated only for candidal vulvovaginitis. However, the active ingredient, Miconazole Nitrate, is used in different formulations and strengths for topical use on the skin to treat other conditions, such as athlete’s foot, jock itch, and ringworm.

Q: Is Vagistat-3 a prescription medicine?

According to the FDA, this product is classified as a Human OTC Drug Label, meaning it is available to consumers over-the-counter without requiring a prescription from a doctor.

Q: Can men use Vagistat-3?

The Vagistat-3 product is formulated with an intravaginal applicator and is indicated for the treatment of vulvovaginal candidiasis. Official labeling for this specific use is directed toward adult women and adolescents 12 years of age and over.

Q: Are there different strengths or types of Vagistat-3?

Vagistat-3 is described as a 3-day therapy containing 200 mg suppositories and a 2% cream. The active ingredient, Miconazole Nitrate, is also available from various manufacturers in other strengths and treatment courses, such as 7-day regimens.

Q: What if the symptoms come back after using Vagistat-3?

Official warnings state that if vaginal yeast infections recur often, such as once a month or three times in six months, a health professional should be consulted before using the product again. Frequent recurrence is described as a condition requiring consultation with a health professional.

Q: Can Vagistat-3 affect sex life or intimacy?

The official product use restrictions detail that vaginal intercourse is generally avoided during the treatment period. Additionally, the product’s oil-based components may damage the material of latex or rubber barrier contraceptives like condoms and diaphragms.

Q: Is there a generic version of Vagistat-3?

Vagistat-3 contains the active ingredient Miconazole Nitrate. The FDA classifies the drug as having an Abbreviated New Drug Application status, which is the regulatory pathway used for equivalent generic medications.

Q: Does Vagistat-3 expire, and is it safe to use after the expiration date?

The product has a specific expiration date printed on the carton or container. Official instructions state that medication which is no longer needed or has expired should be thrown away in accordance with local guidelines for safe drug disposal.

Q: What is the main difference between a one-day and a three-day treatment?

Regulatory review documents describe that three-day regimens containing Miconazole Nitrate have been associated with a similar efficacy and safety profile compared to the seven-day treatment courses studied in clinical trials.

Q: Can Vagistat-3 interact with certain vitamins or supplements?

The product labeling specifically warns of an interaction with the prescription blood thinner warfarin. Regulatory text specifies that users should consult a pharmacist or doctor regarding any prescription or nonprescription medicine, vitamins, or supplements being taken.

Q: Does Vagistat-3 contain gluten or common allergens?

The official product labeling provides a list of all active and inactive ingredients (excipients) used in the formulation. Patients are advised to review this list to check for the presence of any known allergens or sensitive components.

Q: Is Vagistat-3 known to cause stomach upset or nausea?

The official label for Miconazole Nitrate lists symptoms such as nausea and vomiting among the potential effects. Regulatory information specifies that consultation with a doctor is necessary if these or other systemic symptoms occur while using the product.

Q: Can Vagistat-3 be used for recurring infections?

Official warnings state that if a person experiences frequent vaginal yeast infections, such as once a month or three times in six months, they must ask a doctor before use. This consultation is required before repeating treatment, which allows a health professional to evaluate the condition.

Q: Why do some people experience vaginal irritation with Vagistat-3?

Official labeling notes that a mild increase in vaginal burning, itching, or irritation may occur as the product begins working. These local effects are listed among the common adverse events associated with the use of the medicine.

Q: Does Vagistat-3 contain probiotics?

The product labeling lists all active and inactive components used in the formulation, including the active antifungal agent, Miconazole Nitrate. Probiotics are not listed among the ingredients in the official regulatory label for this product.

Q: What makes Vagistat-3 different from treatments sold under a different name?

The key difference is defined by the active ingredient and dosage regimen. Vagistat-3 contains the active ingredient Miconazole Nitrate and is supplied as a specific 3-day regimen for local treatment of vulvovaginal candidiasis.

Q: Can I use Vagistat-3 if I am sensitive to certain dyes or perfumes?

The official regulatory label provides a complete list of all inactive ingredients (excipients) used in the formulation. Patients who are sensitive to components such as dyes or perfumes can review this list to check for the presence of known irritants.

Q: Is the formula of Vagistat-3 oil-based or water-based?

The product contains oil-based components in its formulation. This is noted in regulatory warnings which state that these components may damage latex products, such as condoms and diaphragms.

Q: How quickly do most patients notice symptom relief with Vagistat-3?

The official product labeling directs users to consult a health professional if symptoms do not get better in 3 days. This instruction sets the expectation that symptom improvement should begin within the first three days of treatment.

Q: Is there a maximum number of times you can use Vagistat-3 per year?

Regulatory labeling instructs users to consult a doctor if vaginal yeast infections occur often, such as once a month or three times in six months. This professional consultation is required before repeating treatment, effectively limiting the frequency of self-treatment based on recurrence patterns.

Q: What if I experience itching that gets worse after starting Vagistat-3?

Official warnings state that if symptoms do not get better in 3 days, or if the user develops a rash, hives, or abdominal pain, they should stop use and ask a doctor. Regulatory information describes worsening symptoms as a condition that requires the user to stop the treatment and seek professional guidance.

Q: Is Vagistat-3 effective against types of yeast other than Candida?

The indication section of the regulatory labeling states that Miconazole Nitrate is effective only for candidal vulvovaginitis. This term refers specifically to infections caused by Candida species.

Q: Why do doctors recommend Vagistat-3 for some people?

Doctors may recommend the product because it is officially indicated for the local treatment of vulvovaginal candidiasis (yeast infections). Regulatory bodies classify the active ingredient as an effective azole antifungal agent for this condition.

Q: What happens if a child accidentally swallows Vagistat-3?

Official labeling includes the strong warning to Keep out of reach of children. The labeling specifies that in the event the medication is swallowed, immediate medical help or contact with a Poison Control Center is necessary.

Q: Can Vagistat-3 be bought online without any consultation?

Since the product is classified by the FDA as an Over-the-Counter (OTC) Drug, it can typically be purchased online or in stores without requiring a prescription or consultation from a doctor.

Vagistat-3 (Miconazole Nitrate) must be stored and handled according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

The product must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). Avoid excessive heat (over 25 C or 77 F) for storage. The medication must be kept out of reach of children. If swallowed, immediate medical help is required.

Handling and Disposal Requirements

Do not use the vaginal suppositories if the printed wrapper is torn, open, or incompletely sealed. Similarly, do not use the external cream if the seal over the tube opening has been punctured. After use, the disposable applicators must be thrown away and not flushed in the toilet. Unused or expired medication should be disposed of in line with local guidelines for safe drug disposal.